Friday, May 30, 2025

Latest

Psyched Wellness Moves To Next Stage Of Pre-Clinical Trials With Mushroom Extract

Psyched Wellness (CSE: PSYC) continues to execute on its strategy as it pertains to the amanita muscaria mushroom. The company, through its contract research organization, KGK Science, has now begun the next pre-clinical trial study on its proprietary extract, referred to as AME-1.

The next round of pre-clinical trials focuses on the beneficial or adverse health extracts of the compound, with the trial referred to as a conditioned placement preference study. The study itself reportedly works by comparing characteristics of the association of the extract in an environment, to the association in another environment without the extract.

Effectively, the study will look into whether the compound developed by Psyched has any abuse potential. The trial is a means of determining whether psychological or physical dependence of the substance can be formed around the extract.

“In conjunction with the other studies the Company is conducting, this trial will bolster Psyched’s toxicological assessment of AME-1 and provide critical knowledge of any behavioral and neurological functional changes in a scientific setting. This is another key step in determining a safe dose of AME-1 for human consumption and moves Psyched closer to being able to bring our Amanita-based CPG products to market,” commented David Shisel, COO of Psyched Wellness.

Psyched Wellness last traded at $0.135 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

First Majestic Makes Second Major Discovery At Santa Elena In Just A Year

Related News

Psyched Wellness Completes 14 Day Oral Toxicity Preclinical Study For Proprietary Extract

Psyched Wellness (CSE: PSYC) this morning announced the results of its initial 14-day oral toxicity...

Tuesday, July 6, 2021, 08:58:10 AM

Psyched Wellness Sees Positive Results From Amanita Muscaria Toxicology Report

Psyched Wellness (CSE: PSYC) has completed its toxicology assessment on that of Amanita Muscaria, the...

Monday, December 7, 2020, 07:56:50 AM

Psyched Wellness Increases Bought Deal To $5.5 Million

Psyched Wellness (CSE: PSYC) has increased the size of its bought deal private placement as...

Monday, January 25, 2021, 07:09:05 AM

Psyched Wellness Adds Amanita Muscaria Expert To Advisory Board

Kevin Feeney has joined the advisory board of that of Psyched Wellness (CSE: PSYC) as...

Thursday, November 26, 2020, 07:16:39 AM

Psyched Wellness Launches Study On Mushroom Extract Focused On Gut Health

Psyched Wellness (CSE: PSYC) this morning issued a very brief press release related to ongoing...

Tuesday, March 30, 2021, 08:31:58 AM